On the prickly issues facing the Menin inhibitors

December 13, 2022/in Currents

https://kuraoncology.com/wp-content/uploads/BSB-Reprint-ASH22-Menin-blog_img.png 646 1246 Ellie Solorio /wp-content/uploads/kura-logo.svg Ellie Solorio2022-12-13 08:00:212023-01-03 11:59:24On the prickly issues facing the Menin inhibitors

About Us
Our Commitment
The Story Behind Our Name
Leadership
Board of Directors

Our Approach
Precision Medicines
Overcoming Resistance
Novel Biomarkers

Pipeline
Ziftomenib
Tipifarnib
KO-2806
Posters and Publications
Access to Investigational Drugs Outside a Clinical Study

Patients & Caregivers
Acute Leukemias
Head & Neck Cancer

Clinical Trials
Overview of Clinical Trials
Ziftomenib Clinical Trials
KOMET-001 – AML
KOMET-007 – AML
KOMET-008 – AML
Tipifarnib Clinical Trials
KURRENT-HN – HNSCC
KO-2806 Clinical Trials
FIT-001 – Solid Tumors

Investors & Media
Overview
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Analyst Coverage
FAQs
Contact

Careers
Values
Life at Kura
Benefits
Open Positions

Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

Liquid Biopsies Guide the Development of Cancer Drugs

Navigating dose optimization requirements as a small biotech

Scroll to top